奥德赛制药
ODTX
17.17
-0.40
-2.28%
奥德赛制药
US · ODTX
#3348 按市值排名
上市于 2026
17.17
-0.40
-2.28%
实时 - 追踪5344个代码 - 心跳于563秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
涨跌不一/平稳
- 最近一期（2026/Q3）披露持股的机构数量减少了1家。
- 机构持股总比例基本持平。
机构持股
- 机构持股比例
- 95.02% -0.06pp
- 机构数量
- 63 -1
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
VC/PE Fund60.92%
Mutual Fund16.24%
Hedge Fund13.32%
Public Company4.50%
Individual/Insider2.39%
Other2.59%
主要股东 截至 2026-06-30
FMR
10.81% · 5.18M 股
SR One Capital Management, LP
7.92% · 3.79M 股
TPG Capital, L.P.
7.70% · 3.69M 股
Jeito Capital S.A.
7.70% · 3.69M 股
Lightspeed Management Company, LLC
7.53% · 3.61M 股
Institutional Venture Partners
7.53% · 3.61M 股
Dimension Management, L.P.
6.96% · 3.33M 股
OrbiMed Advisors LLC
6.26% · 3.00M 股
Sanofi
4.16% · 1.99M 股
Deerfield Management Company, L.P.
2.18% · 1.05M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 19次买入 · 5次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Gary Glick | Chief Executive Officer | 0.87% |
| Jeffrey Leiden | Independent Chairperson | 0.63% |
| Ian Smith | Independent Director | 0.51% |
| Jason Haas | Chief Financial Officer | 0.13% |
| Valerie Odegard | Independent Director | 0.13% |
| Natalie Dales | Chief of Research Operations & Portfolio Strategy | 0.08% |
| Shelley Chu | Independent Director | 0.02% |
| Anthony Opipari | -- | 0.02% |
| TPG Capital, L.P. | -- | -- |
| Jolie Siegel | General Counsel | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-05-10 | TPG Capital, L.P. | -- | Other Acquisition | +423,111 | -- |
| 2026-05-10 | TPG Capital, L.P. | -- | Other Disposition | -2,351 | $18.00 |
| 2026-05-10 | TPG Capital, L.P. | -- | Private Acquisition | +1,388,889 | $18.00 |
| 2026-05-10 | TPG Capital, L.P. | -- | Other Derivative Disposition | -423,111 | -- |
| 2026-05-10 | TPG Capital, L.P. | -- | Derivative Exercise and Retained | +1,880,497 | -- |
| 2026-05-10 | Jeffrey Leiden | Independent Chairperson | Derivative Exercise and Sale | -17 | $18.00 |
| 2026-05-10 | Jeffrey Leiden | Independent Chairperson | Derivative Exercise and Retained | +31,644 | -- |
| 2026-05-10 | Shelley Chu | Independent Director | Private Acquisition | +11,111 | $18.00 |
| 2026-05-10 | Gary Glick | Chief Executive Officer | Derivative Exercise and Retained | +27,386 | -- |
| 2026-05-10 | Anthony Opipari | -- | Derivative Exercise and Sale | -4 | $18.00 |
| 2026-05-10 | Anthony Opipari | -- | Derivative Exercise and Retained | +7,502 | -- |
| 2026-05-10 | SR One Capital Management, LP | -- | Private Acquisition | +555,555 | $18.00 |
| 2026-05-10 | SR One Capital Management, LP | -- | Derivative Exercise and Sale | -1,780 | $18.00 |
| 2026-05-10 | SR One Capital Management, LP | -- | Derivative Exercise and Retained | +3,239,328 | -- |
| 2026-05-10 | Dimension Management, L.P. | -- | Private Acquisition | +1,111,111 | $18.00 |
| 2026-05-10 | Dimension Management, L.P. | -- | Derivative Exercise and Retained | +1,709,543 | -- |
| 2026-05-07 | Jeffrey Leiden | Independent Chairperson | Private Acquisition | +5,000 | $20.00 |
| 2026-05-07 | Jason Haas | Chief Financial Officer | Open Market Acquisition | +1,000 | $20.00 |
| 2026-05-06 | TPG Capital, L.P. | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-05-06 | Jeffrey Leiden | Independent Chairperson | Other Derivative Acquisition | +626,220 | $18.00 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
奥德赛制药 讨论区 0 条评论